This record provides bibliographic details and links to the original research. An editorial study breakdown is not available.
Read the original research
Once-weekly IcoSema versus multiple daily insulin injections in type 2 diabetes management (COMBINE 3): an open-label, multicentre, treat-to-target, non-inferiority, randomised, phase 3a trial.
The lancet. Diabetes & endocrinology, 13(7), 556-567
Citation
Billings, Liana K; Andreozzi, Francesco; Frederiksen, Marie; Gourdy, Pierre; Gowda, Amoolya; Ji, Linong; Pletsch-Borba, Laura; Suzuki, Ryo; Unnikrishnan, A G; Vianna, André G D. (2025). Once-weekly IcoSema versus multiple daily insulin injections in type 2 diabetes management (COMBINE 3): an open-label, multicentre, treat-to-target, non-inferiority, randomised, phase 3a trial.. The lancet. Diabetes & endocrinology, 13(7), 556-567. https://doi.org/10.1016/S2213-8587(25)00052-X